Delving into the Latest Updates on Biperiden Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1-Bicyclo[2.2.1]hept-5-en-2-yl-1-phenyl-3-piperidin-1-yl-propan-1-ol, alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol, alpha-bicyclo[2.2.1]hept-5-en-2-yl-alpha-phenyl-1-piperidinepropanol

+ [7]

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Dyskinesia, Drug-InducedParkinsonian Disorders

Inactive Indication

Parkinson Disease

Originator Organization

AbbVie, Inc.

Active Organization

Sumitomo Pharma Co., Ltd.

Inactive Organization

AbbVie, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (08 Sep 1959),

Parkinson Disease

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H30ClNO

InChIKeyRDNLAULGBSQZMP-UHFFFAOYSA-N

CAS Registry1235-82-1

One of the most important neurological consequences following Traumatic Brain Injury (TBI) is the development of post traumatic epilepsy (PTE). Nevertheless, there is still no effective therapeutic intervention to reduce the occurrence of PTE. In previous studies with animals models of epilepsy, the biperiden decreased the incidence and intensity of spontaneous epileptic seizures besides delaying their appearance. The aim of this study is the evaluation of biperiden as antiepileptogenic drug to prevent PTE and also the determination of side effects, evaluating its cost-effectiveness in patients with moderate and severe TBI.

Start Date10 Jan 2023

Sponsor / Collaborator

Sociedade Beneficiente de Senhoras Hospital Sírio Libanês

[+6]

IRCT20200407046981N44

/ RecruitingNot Applicable

Comparative bioequivalence study of the Biperiden 4-mg extended-release tablets manufactured by Vana Darou Gostar Pharmaceutical Company versus Akineton® (Desma Company)

Start Date30 Oct 2022

Sponsor / Collaborator-

100 Clinical Results associated with Biperiden Hydrochloride

Login to view more data

100 Translational Medicine associated with Biperiden Hydrochloride

Login to view more data

100 Patents (Medical) associated with Biperiden Hydrochloride

Login to view more data

1,097

Literatures (Medical) associated with Biperiden Hydrochloride

01 May 2025·NEUROSCIENCE LETTERS

Evaluation of the effect of biperiden (cholinergic muscarinic receptor antagonist) on ethanol self-administration in rats

Article

Author: Cruz, Fábio Cardoso ; Leão, Rodrigo Molini ; Palombo, Paola ; Matos Mendes Ferreira Badaro, Sara Emi ; Teodoro, Lucas ; Lira, Clarice Ribeiro ; Fernandes Galduróz, José Carlos

Evidence from the literature suggests that alcohol use disorder (AUD) is closely associated with alterations in neuronal plasticity and the memory system, related to modifications in muscarinic receptors. The present study aimed to investigate the effects of systemic injection of biperiden, a muscarinic cholinergic antagonist, in experimental protocols of progressive ratio, 24-hour binge alcohol consumption, and reinstatement of context-induced ethanol self-administration. The results demonstrated that biperiden at doses of 5 and 10 mg/kg (i.p.) effectively reduced the animals' motivation for alcohol consumption, as evidenced by decreased responses on the active lever and a reduction in the last ratio achieved in the progressive ratio protocol. Furthermore, these same doses significantly reduced ethanol consumption in the 24-hour binge protocol. Treatment with biperiden at doses of 1, 5, and 10 mg/kg also attenuated alcohol-seeking behavior after re-exposure to the context associated with ethanol self-administration. These findings suggest that biperiden may have therapeutic potential in the treatment of alcohol use disorder, indicating that modulation of the cholinergic system could be a promising avenue for further investigation.

10 Mar 2025·Cureus Journal of Medical Science

Uncommon Extrapyramidal Reaction to Ondansetron

Article

Author: Moreira, Catarina ; Gaspar, João ; Dias, Carolina S ; Santos, Maria

We describe the case of a 77-year-old man, who was admitted for the initiation of chemotherapy for stage IV small cell lung cancer without cerebral metastases. On the first day post-admission, the patient developed altered mental status and right-sided weakness after premedication with ondansetron and dexamethasone. Symptoms resolved spontaneously within 90 minutes. An ischemic event was suspected despite unremarkable brain imaging. Prophylactic anticoagulation and statins were initiated. Five days later, a second episode of altered mental status, anisocoria, facial paresis, and severe dysarthria occurred following ondansetron administration. Bloodwork revealed significant hyponatremia (116 mEq/L), suggesting Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), despite this suspicion, there was no further investigation to confirm this diagnosis due to rapid symptom reversal after biperiden administration, implicating an adverse reaction to ondansetron. Ondansetron and metoclopramide were discontinued, hyponatremia was corrected, and no further episodes occurred during the hospital stay. This case highlights the necessity of awareness for adverse reactions of ondansetron that can mimic cerebrovascular events and the need for a thorough revision of medication in complex cases.

22 Feb 2025·Oxford Medical Case Reports

Prolonged extrapyramidal syndrome due to metoclopramide overdose: a rare case report

Article

Author: Zakariaei, Zakaria ; Omrani, Arshia ; Ramzani, Yasin ; Malakian, Abdollah ; Omrani, Alireza

Abstract:

Metoclopramide is a useful antiemetic drug that is widely used in medical emergencies. This drug can cause extrapyramidal side effects that are worrying. An 18-year-old girl student unintentionally consumed a large dose (60 mg) of metoclopramide, exceeding the recommended therapeutic dose, for the management of nausea and vomiting. Approximately six hours after the ingestion of the medication, she developed neck dystonia and upward deviation of the eyes. Seeing these symptoms and worrying about their child’s physical condition, the parents took her to the local medical center in northern Iran. With the diagnosis of the extrapyramidal syndrome and intramuscular administration of biperiden 5 mg ampoule twice at 12-h intervals, unfortunately, the symptoms did not improve and finally he was referred to our hospital. Dystonic reactions caused by metoclopramide can be misdiagnosed and it is necessary to be monitored and treated appropriately to reduce the family’s concern about its unpleasant side effects.

1

News (Medical) associated with Biperiden Hydrochloride

07 Feb 2025

·endpts.com

Belgian regulator recommends blocking Indian drugmaker's API production

Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for Medicines and Health Products for 24 issues related to Maithili’s active pharmaceutical ingredient manufacturing. An inspection of the manufacturer’s factory in Andhra Pradesh, India, ending in November 2024 revealed the problems, according to a report published by the European Medicines Agency and the Belgian regulator. Due to the discrepancies, the FAMHP recommended that Maithili be removed as a manufacturer of active substances and intermediates. The agency also recommended blocking Maithili from supplying products made at the Andhra Pradesh facility, as long as there are alternate suppliers and it wouldn’t cause drug shortages. In particular, the report states the company should be suspended from making its biperiden hydrochloride product, which is a muscarinic receptor antagonist used to treat the muscle spasms and stiffness caused by Parkinson’s disease. The regulator also recommended an assessment of Maithili’s products to decide if the drugmaker should recall batches of its APIs. In addition, all imported products from the Andhra Pradesh factory should be retested, the report states. The 24 deficiencies outlined in the report include issues regarding the cleanliness and maintenance of manufacturing equipment, which could lead to contamination and cross-contamination of APIs. In addition to manufacturing commercial APIs and other raw materials, Maithili Life Sciences also offers research and development capabilities for intermediates and other chemicals, according to its website. It ships its products globally and domestically.

100 Deals associated with Biperiden Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02246	Biperiden Hydrochloride	N04AA02	DB00810

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Dyskinesia, Drug-Induced	Japan	Sumitomo Pharma Co., Ltd.	28 Feb 1964
Parkinsonian Disorders	Japan	Sumitomo Pharma Co., Ltd.	28 Feb 1964
Parkinson Disease	United States	AbbVie, Inc.	08 Sep 1959

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01251393 (CTgov)	Phase 3	Cocaine-Related Disorders	111	Biperiden (Biperiden)	xbqxoolwdz(fpthbthgam) = bzdpgmjwzk qrjzklbctu (hjvsmtkokp, 2.6) View more	-	28 Feb 2020
				Placebo (Placebo)	xbqxoolwdz(fpthbthgam) = jzcmehopra qrjzklbctu (hjvsmtkokp, 2.6) View more